| Literature DB >> 26101769 |
Yoon-Mi Lee1, Byeng Chun Song1, Kyung-Jin Yeum1.
Abstract
The safety of anesthesia, which is an important step for surgery, can be determined by its impact on oxidative stress and inflammation. The effects of volatile anesthetics such as isoflurane and sevoflurane on oxidative stress and inflammation are reviewed in various (1) cell lines, (2) rodents, and (3) human studies. Isoflurane and sevoflurane are reported to have antioxidant and anti-inflammatory effects in all cells with exception of neuronal cell lines. In addition, various animal studies have indicated that isoflurane and sevoflurane were not only safe but also reduced oxidative stress and inflammation in rodent models. In human studies, oxidative stress, inflammation, and DNA damage were not affected by isoflurane and sevoflurane in patients undergoing minor incision surgeries. On the other hand, elevated oxidative stress, inflammation, and DNA damage have been observed in patients undergoing major surgeries such as abdominal and orthopedic surgeries, hysterectomy, cholecystectomy, and thoracotomy. Although impact of anesthetics on oxidative stress and inflammation is still not clear due to the variations of patients' health conditions, types of surgery and the quantities of anesthetics, isoflurane, and sevoflurane can be considered safe anesthetics with respect to their effect on oxidative stress and inflammation in subjects undergoing minor surgery. Continuous effort evaluating the safety of anesthesia in various aspects is required.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26101769 PMCID: PMC4458520 DOI: 10.1155/2015/242709
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Structures of isoflurane and sevoflurane.
Figure 2Biomarkers of oxidative damaged macromolecules. Oxidative stress leads to the damage of macromolecules such as DNA, lipid, and protein. The oxidative damaged macromolecules can be determined by their by-product under oxidative stress. MDA: malondialdehyde; 4-HNE: 4-4-hydroxy-2-nonenal; 8-OHdG: 8-hydroxydeoxyguanosine; AGE: advanced glycation end products; ALE: advanced lipoxidation end products.
Figure 3Activation of inflammatory signaling. Extracellular stimuli such as oxidative stress, TLRs activation, and infection lead to activating MAPK pathways by phosphorylation of ERK, JNK, and p38. Then, NF-κB is translocated to the nucleus, which in turn binds to DBD of its target genes, proinflammatory cytokines, proinflammatory enzymes, and CRP. The target genes of NF-κB are well known for aggravating inflammation responses. TLRs: toll-like receptors; ERK: extracellular signal-regulated kinases; JNK: c-Jun NH2-terminal; DBD: DNA binding domain; IL: interleukin; TNF-α: tumor necrosis factor-α; COX-2: cyclooxygeneases-2; iNOS: inducible nitric oxide synthase; LOX: lipoxygenase; CRP: C-reactive protein.
Figure 4Interrelation of oxidative stress and inflammation. Oxidative stress-induced inflammatory cascades cause the inflammation, which in turn increases oxidative stress.
Effects of volatile anesthetics on oxidative stress and inflammation in cells.
| Disease model | Stimulus | Cells | Anesthetics | Effect | Reference |
|---|---|---|---|---|---|
| Sepsis | LPS | HUVEC (human) | Sevoflurane | Anti-inflammatory effects | [ |
|
| |||||
| Acute lung injury | LPS | AEC (rat) | Sevoflurane | Anti-inflammatory effects | [ |
|
| |||||
| MODS | Zymosan | Kupffer cells (murine) | Isoflurane | Antioxidant effects |
[ |
| Anti-inflammatory effects | |||||
|
| |||||
| Inflammation | TNF- | Monocytic THP-1 (human) | Sevoflurane, isoflurane | Anti-inflammatory effects | [ |
|
| |||||
| POCD | LPS | Microglial BV-2 (murine) | Sevoflurane, isoflurane | No effect on cytokine levels | [ |
|
| |||||
| Neuron injury | OGD | SH-SY5Y (human) | Isoflurane | Increased neuronal cell death | [ |
LPS, lipopolysaccharides; HUVEC, human vascular endothelial cells; AEC, alveolar epithelial cells; MODS, multiple organ dysfunction syndrome; TNF-α, tumor necrosis factor-α, POCD, postoperative cognitive dysfunction; OGD, oxygen-glucose deprivation.
Effects of volatile anesthetics on oxidative stress and inflammation in rodents.
| Disease model | Inducer | Anesthetics | Effects | Reference |
|---|---|---|---|---|
| Cardiac ischemia in rat myocyte | Hypoxia | Isoflurane | Antioxidant effects |
[ |
| Hydrogen peroxide | Antiapoptosis effects | |||
| Neutrophil | Cardioprotective effects | |||
|
| ||||
| Cerebral ischemia in rats | Cerebral artery occlusion | Sevoflurane, isoflurane | Antioxidant effects |
[ |
| Anti-inflammatory effects | ||||
|
| ||||
| Diabetic rats | Mutation in the | Isoflurane | Antioxidant effects |
[ |
| Decreased myocardial contraction | ||||
|
| ||||
| MODS in mice | Zymosan | Isoflurane | Anti-inflammatory effects | [ |
|
| ||||
| MODS in mice | Zymosan | Isoflurane | Anti-inflammatory effects | [ |
|
| ||||
| MODS in mice | Zymosan | Isoflurane | Antiapoptosis effects |
[ |
| Anti-inflammatory effects | ||||
|
| ||||
| Inflammation in rats | LPS | Sevoflurane | Anti-inflammatory effects | [ |
|
| ||||
| Inflammation in rats | LPS | Isoflurane | Anti-inflammatory effects | [ |
|
| ||||
| Sepsis in mice | Cecal ligation and puncture | Sevoflurane | Anti-inflammatory effects | [ |
|
| ||||
| Sepsis in rat | Cecal ligation and puncture | Sevoflurane, isoflurane | Anti-inflammatory effects | [ |
|
| ||||
| Rat liver transplantation | — | Sevoflurane | Antioxidant effects | [ |
MODS, multiple organ dysfunction syndrome; LPS, lipopolysaccharide.
Effects of volatile anesthetics on oxidative stress and inflammation in humans.
| Subject of study | Anesthetics | Effects | References |
|---|---|---|---|
| Patients | Isoflurane, sevoflurane | Increased DNA damage | [ |
|
| |||
| Patients | Sevoflurane | Increased DNA damage | [ |
|
| |||
| Patients | Isoflurane | Increased inflammation response | [ |
|
| |||
| Patients | Isoflurane | Increased inflammation response | [ |
|
| |||
| Patients | Sevoflurane | Pulmonary dysfunction by increased inflammation response | [ |
|
| |||
| Patients | Isoflurane, sevoflurane | No alteration of DNA damage | [ |
|
| |||
| Patients | Isoflurane | No alteration of DNA damage | [ |
|
| |||
| Patients | Sevoflurane | Antioxidant activity | [ |
|
| |||
| Patients | Isoflurane | No induction of oxidative stress |
[ |
| No induction of inflammation | |||
|
| |||
| Patients | Sevoflurane | No alteration of redox state | [ |
|
| |||
| Patients | Sevoflurane | Anti-inflammatory effects | [ |
|
| |||
| Patients | Sevoflurane | Anti-inflammatory effects | [ |
|
| |||
| Patients | Isoflurane, sevoflurane | No alteration of cytokine profiles | [ |
|
| |||
| Operating room personnel | Sevoflurane | No alteration of DNA damage | [ |
|
| |||
| Operating room personnel | Isoflurane | Increased DNA damage | [ |